Description
: Glyxambi is a fixed-dose combination medication containing 25 mg of empagliflozin and 5 mg of linagliptin. It is used to improve blood sugar control in adults with type 2 diabetes mellitus, alongside diet and exercise. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that works by increasing glucose excretion through urine, while linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon levels, particularly after meals. Together, these actions help lower blood glucose levels and may reduce the risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
.jpg)
Change Language